High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study

Abstract

The objective of this study is to describe the characteristics and outcomes of rheumatic and musculoskeletal disease (RMD) patients who were treated with rituximab and had suspected or confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In this descriptive study, RMD patients who were treated with rituximab in the last 12 months at the Rheumatology Department of our hospital were screened for SARS-CoV-2 infection via telephone interview and a comprehensive review of clinical health records (01/02/2020–26/05/2020). Those with probable or confirmed SARS-CoV-2 infection were included. In total, 76 patients were screened. Of these, 13 (17.1%) had suspected or confirmed SARS-CoV-2 infection. With regard to these 13 patients, the median age at coronavirus disease (COVID-19) diagnosis was 68 years (range 28–76 years) and 8 (61.5%) were female. Five patients had rheumatoid arthritis, three had systemic vasculitis, two had Sjögren syndrome, and two had systemic lupus erythematosus. Additionally, seven patients (53.8%) had pulmonary involvement secondary to RMD. Eight patients (61.5%) developed severe disease leading to hospitalization, and seven developed bilateral pneumonia and respiratory insufficiency. Of the eight hospitalized patients, five (62.5%) fulfilled the acute respiratory distress syndrome criteria and three developed a critical disease and died. Our cohort had a high rate of severe disease requiring hospitalization (61.5%), with bilateral pneumonia and hyperinflammation leading to a high mortality rate (23.1%). Treatment with rituximab should be considered a possible risk factor for unfavorable outcomes in COVID-19 patients with RMD. However, further study is required to confirm this association.

Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was first reported in Wuhan, China, in December 2019. The spread of SARS-CoV-2 infection was declared a pandemic in March 2020 by the World Health Organization with 800,906 deaths among 2,057,288 confirmed cases, which accounted for 3.89% of mortality among infected individuals [1]. Madrid, Spain, is a high-impact area in terms of SARS-CoV-2 infection, with official data showing more than 74,886 infected people and 8,451 infection-related deaths to date (24/08/2020) [2]. SARS-CoV-2 is an enveloped, single-stranded RNA virus and a member of β-coronaviruses, such as severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus. Similar to SARS-CoV, SARS-CoV-2 enters human cells using angiotensin-converting enzyme2 and causes coronavirus disease (COVID-19). COVID-19 severity ranges from asymptomatic to severe, and the disease can result in acute respiratory distress syndrome (ARDS) and cytokine storm, which have led to death in 3–10% of the infected population.

Patients with rheumatic and musculoskeletal diseases (RMDs) are at high risk for infections related to their disease, comorbidities, or immunosuppressive treatments [3], but recent studies regarding COVID-19 did not support higher mortality in these patients [4–7]. However, there are few data regarding specific risk factors for unfavorable outcomes, such as specific diseases or immunosuppressive drugs [5]. Further, some reports have suggested the worst prognosis for RMD patients who were treated with rituximab and developed SARS-CoV-2 infection [8, 9]. Our objective was to describe the clinical characteristics and outcomes of our cohort of RMD patients who were treated with rituximab and had suspected or confirmed SARS-CoV-2 infection.

Methods

In this descriptive study, RMD patients who were treated with rituximab in the last 12 months at the Rheumatology Department of our hospital (Hospital Universitario Ramón y Cajal, Madrid, Spain) were screened for SARS-CoV-2 infection via telephone interview and a comprehensive review of clinical health records (02/01/2020–26/05/2020). Those with probable or confirmed SARS-CoV-2 infection were included. There were no exclusion criteria.

SARS-CoV-2 infections were confirmed if patient’s nasopharyngeal swabs were positive for SARS-CoV-2, as determined via real-time reverse transcription polymerase chain reaction (RT-PCR) and/or characteristic bilateral infiltrates were found on chest radiographs/computerized tomography (CT) scans. A probable SARS-CoV-2 infection was defined as the presence of two or more symptoms related to COVID-19 (fever, dry cough, dyspnea, odynophagia, myalgia, anosmia, or ageusia) when other causes were excluded. TaqMan 2019-nCoV Assay Kit v1 (Thermo Fisher Scientific Inc., Franklin, MA, USA) was used to detect viral RNA. It has high efficiency, similar to other commercially available RT-PCR tests [10].

Hyperinflammation was defined in accordance with the ongoing clinical trials and recent studies (lymphocyte count < 1000 cells/mL and two of the following criteria: serum ferritin level > 500 ng/mL, lactate dehydrogenase level > 300 U/L, and d-dimer level > 1000 ng/m), and was evaluated within the first 7 days of hospital admission [11].

The current study is a sub-analysis of a larger study focused in SARS-CoV-2 infection in RMD patients (study number: 136/20), and was approved by the local ethics committee of our hospital (comité de ética de la investigación con medicamentos del Hospital Universitario Ramón y Cajal) on 05/05/2020. All patients provided informed consent to participate and for publication prior to their inclusion.

Categorical variables are presented as numbers and percentages. Continuous variables are expressed as median (interquartile range [IQR] or range).

Results

Patient characteristics

We screened a total of 76 patients. Of these 76 patients, 63 (82.9%) did not exhibit COVID-19 symptoms or signs of suspected SARS-CoV-2 infection, and 13 (17.1%) had suspected or confirmed SARS-CoV-2 infection. The baseline characteristics of these 13 patients are described in Table 1. The median age at COVID-19 diagnosis was 68 years (range 28–76 years) and eight (61.5%) were female. Further, rheumatoid arthritis (RA) was the most frequent RMD (6/13, 46.2%) observed in patients with suspected or confirmed SARS-CoV-2 infection, followed by systemic vasculitis (3/13, 23%), Sjögren syndrome (2/13, 15.4%), and systemic lupus erythematosus (SLE) (2/13, 15.4%). With regard to other immunosuppressive treatments prescribed for their RMD, six patients were treated with methotrexate, and one patient was treated with hydroxychloroquine (HCQ). Further, of the 13 suspected and confirmed SARS-CoV-2 infection patients, 7 (53.8%) were on low-dose corticosteroid treatment (≤ 10 mg/day). Moreover, the main comorbidities observed in this group were arterial hypertension (61.2%), dyslipidemia (46.2%), chronic obstructive pulmonary disease (COPD) or asthma (46.2%), cardiovascular disease (23.1%), and diabetes mellitus (7.7%). Additionally, pulmonary involvement secondary to RMD was present in 7 of the 13 patients (53.8%), and interstitial lung disease (ILD) was observed in 3 of those 7 patients (42.9%).

Table 1.

Baseline characteristics

	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5	Patient 6	Patient 7	Patient 8	Patient 9	Patient 10	Patient 11	Patient 12	Patient 13
Age, years	71	55	68	48	62	28	72	69	76	68	69	67	54
Sex	Male	Female	Male	Female	Female	Female	Male	Female	Male	Female	Male	Female	Female
RMD	RA	pSS	RA	RA	pSS	SLE	Vasculitisa	SLE	Vasculitisa	RA + sSS	Vasculitisa	RA + sSS	RA + sSS
Time from diagnosis, years	13	7	10	12	35	8	21	15	19	28	5	38	17
Pulmonary Involvement 2º to RMD	Rheumatoid nodules	ILD	ILD	No	No	Pleural effusion	ILD	No	Pulmonary infiltrates	ILD	No	No	No
Comorbidities
HTA	No	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	No	No	No
DL	No	No	Yes	No	No	Yes	No	No	No	Yes	Yes	Yes	Yes
DM	No	No	Yes	No	No	No	No	No	No	No	No	No	No
CV disease	No	No	Yes	No	No	No	No	Yes	Yes	No	No	No	No
COPD	Yes	No	Yes	No	No	No	No	Yes	Yes	Yes	No	No	No
Baseline treatment
Corticosteroids*	No	7,5	10	No	5	5	No	7,5	10	No	No	2,5	No
cDMARDs	MTX	No	MTX	MTX	No	HCQ	No	No	No	No	MTX	MTX	MTX
Rituximab dosage**	Reducedb	Standard	Reducedb	Standard	Standard	Standard	Standard	Standard	Standard	Reducedc	Reducedb	Standard	Standard
Time from last Rituximab administration to COVID symptoms onset, months	11	4	9	3	1	4	4	0	8d	5	6	6	2

ILD interstitial lung disease, HTA hypertension, DM diabetes mellitus, DL dislipemia, CV cardiovascular, COPD chronic obstructive pulmonary disease, MTX methotrexate, HCQ hydroxychloroquine. RA rheumatoid arthritis, RA + sSS rheumatoid arthritis and secondary Sjögren syndrome, pSS primary Sjögren syndrome, SLE systemic lupus erythematosus

*Prednisolone, mg/day. **Standard dosage: 1 g/15 days/6 months or 375 m²/week × 4

^aPatient 7: p-ANCA vasculitis with renal and ILD involvement; Patient 9: c-ANCA vasculitis with renal and pulmonary involvement; Patient 11: c-ANCA vascultis with upper respiratory tract and pseudotumor orbitary involvement

^b1 g/15 days/1 year

^c1 g/15 days/9 months

^dTreatment was delayed due to the pandemic outbreak

With regard to their RMD activity at COVID-19 diagnosis, 76.9% of patients were in remission, 15.4% had low disease activity, and 7.7% had active disease, despite receiving treatment.

Diagnosis and symptoms

The main characteristics of SARS-CoV-2 infection and treatment are summarized in Table 2. Among the 13 patients with suspected or confirmed SARS-CoV-2 infection, 8 (61.5%) had confirmed infections and 5 (38.5%) had suspected infections. The most frequently reported COVID-19 symptoms were fever (61.5%), asthenia (61.5%), cough (61.5%), and dyspnea (61.5%). Diarrhea was present in 38.5% of suspected and confirmed COVID-19 patients. Anosmia and ageusia were only reported in 15.4% and 7.7% of such patients, respectively.

Table 2.

SARS-COV2 infection diagnosis, symptoms and treatment

	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5	Patient 6	Patient 7	Patient 8	Patient 9	Patient 10	Patient 11	Patient 12	Patient 13
SARS-COV2 infection diagnosis	PCR	PCR	Chest-X-ray	Susp.	PCR	Susp.	PCR	Chest-X-ray	PCR	Chest-X-ray	Susp.	Susp.	Susp.
Outcome	Hosp.	Hosp.	Deceased	Amb.	Hosp.	Amb.	Hosp.	Deceased	Deceased	Hosp.	Amb.	Amb.	Amb.
Chest-X-ray/CT scan	Unilateral interstitial pneumonia	Bilateral alveolar pneumonia	Bilateral alveolar pneumonia	NA	Bilateral alveolar pneumonia	NA	Bilateral alveolar pneumonia	Bilateral interstitial pneumonia	Bilateral alveolar pneumonia	Bilateral interstitial pneumonia	NA	NA	NA
Laboratory test
Lymphocytes (cell/mL)	250	200	330	NA	350	NA	450	420	660	1050	NA	NA	NA
LDH (U/L)	423	406	639		383		265	714	801	187
Ferritin (ng/mL)	NA	10,008	120.1		1370		NA	18,869	1993	12
DD (ng/mL)	1390	343	9924		835		1380	2563	2144	664
IL-6 (ng/mL)	NA	5.82	623.1		62.11		NA	153.5	3178	NA
Hyperinflammation	Yes	Yes	Yes	NA	Yes	NA	No	Yes	Yes	No	NA	NA	NA
Ventilatory support	SO	SO	NIVM	None	SO	None	SO	NIMV	NIMV	None	None	None	None
PaO2/FiO2 < 300	Yes	No	Yes	NA	Yes	NA	Yes	Yes	Yes	No	NA	NA	NA
Day of clinical worsening	14	11	3	NA	15	NA	23	10	20	7	NA	NA	NA
SARS-COV2 infection treatment
Oral treatment	HCQ + L/R	HCQ + L/R + AZT	HCQ + AZT	AZT	HCQ + L/R + AZT	None	HCQ + AZT	HCQ + L/R	HCQ + AZT	HCQ + L/R	None	None	None
Corticosteroids*	< 1 mg/kg/day	> 1 mg/kg/day	> 1 mg/kg/day	No	Bolusa	No	> 1 mg/kg/day	Bolusb	Bolusb	No	No	No	No
Tocilizumab	No	No	No	No	No	No	No	No	Yes	No	No	No	No

PCR polymerase chain reaction, Susp. suspected, Hosp. hospitalized, Amb. ambulatory, CT computed tomography, NA not applicable, LDH lactate dehydrogenase, DD d-dimer, SO supplementary oxygen (nasal cannula/oxygen mask), NIMV non-invasive mechanical ventilation, HCQ hydroxychloroquine, L/R lopinavir/ritonavir, AZT azithromycin

*Prednisolone or equivalent

^aIntravenous methylprednisolone 250 mg/day for 3 days

^bIntravenous methylprednisolone 1 g/day for 3 days

With regard to hospitalization, 8 of the 13 patients (61.5%) were treated as inpatients and hospitalized for a median of 10 days (range 4–29 days). All eight patients had confirmed SARS-CoV-2 infections. Furthermore, laboratory tests were only performed for hospitalized patients. Of these eight patients, six (75%) presented with hyperinflammation. Interleukin-6 levels were measured in five patients and found to be elevated in four (80%) of them, as reported in Table 2. Chest radiographs, which were only available for inpatients, showed that seven (87.5%) inpatients had bilateral pneumonia. Repeated chest X-rays or CT scans were performed after a median of 6 days (range 3–11 days) for these seven inpatients and showed that three patients (42.8%) exhibited radiological improvement, one (14.2%) remained stable, and three (42.8%) worsened.

Treatment

All ambulatory patients (n = 5) maintained their treatment with conventional disease-modifying antirheumatic drugs (DMARDs). Additionally, one patient received azithromycin, but no other treatment was prescribed.

All hospitalized patients suspended their conventional DMARD treatment at admission and were prescribed HCQ, along with azithromycin or lopinavir/ritonavir. Corticosteroids were only prescribed for hospitalized patients with severe disease, as determined by the treating clinician. Intravenous methylprednisolone was prescribed to seven of the eight hospitalized patients (87.5%). Of these seven patients, two (28.5%) received 1 g of methylprednisolone per day for 3 days, one (14.3%) received 250 mg of methylprednisolone per day for 3 days, three (42.9%) received > 1 mg/kg of methylprednisolone per day for a median of 8 days, and one (14.3%) received < 1 mg/kg of methylprednisolone per day for 7 days.

Outcomes

All ambulatory patients (n = 5) exhibited favorable outcomes.

All eight hospitalized patients experienced clinical worsening after a median of 12.5 days (range 3–23 days; 62.5% of patients worsened after > 10 days from symptom onset). Respiratory insufficiency requiring the use of supplementary oxygen was observed in seven hospitalized patients (87.5%). Of these seven patients, three (42.9%) required non-invasive mechanical ventilation (NIVM). Additionally, five of the eight hospitalized patients (62.5%) fulfilled the ARDS criteria (PaO₂/FiO₂ < 300 and bilateral pneumonia).

Furthermore, three of the thirteen patients with suspected or confirmed SARS-CoV-2 infection (23.1%) died due to severe ARDS, despite intensive treatment and NIVM. All patients who died had three or more comorbidities and two had pulmonary involvement secondary to RMD. With regard to other complications, an RA patient (Patient 3) who was admitted to our hospital due to multiple osteoporotic fractures developed a pulmonary embolism, despite taking prophylactic heparin. Patient 8, a woman diagnosed with SLE secondary to Evans syndrome and COPD which was treated with chronic supplementary oxygen, developed a secondary Pseudomonas aeruginosa infection.

Discussion

To our knowledge, ours is the first study that describes a cohort of RMD patients who were treated with rituximab and were determined or suspected of having COVID-19 after comprehensive screening. We report a relatively high rate of infection among rituximab-treated RMD patients (13/76, 17%). Additionally, a large portion of our cohort of infected patients (n = 13) was frequently hospitalized (61.5%) and had a high mortality rate (23.1%). Few studies have described SARS-CoV-2 infection among RMD patients and those that undergo immunosuppressive treatments, but all of them have reported lower hospitalization and death rates compared to our patients, with mortality ranging between 0 and 10% [4–6, 11–13]. However, given the small number of patients in these studies, very few have analyzed specific risk factors related to immunosuppressive therapies, and most of them have reported higher hospitalization rates for patients receiving chronic glucocorticoids compared to those not receiving them [4, 6, 8]. Interestingly, one of these studies reported an inverse relationship between anti-TNF therapy and hospitalization [6]. Nevertheless, specific information about rituximab is lacking in most of these studies. Favalli et al. [14] reported on a cohort in which one COVID-19 patient was treated with rituximab. This patient, a 32-year-old woman with systemic sclerosis and pulmonary involvement, died after requiring mechanical ventilation and treatment with tocilizumab. Furthermore, the BIOBADASER cohort (from a multicenter Spanish registry assessing patients treated with biological or synthetic DMARDs) had two SARS-CoV-2-infected patients who were treated with rituximab, one of whom died (91 years old, hypertension, systemic vasculitis) [12]. Another study from Madrid, Spain recently reported that their entire cohort of seven RMD patients who were treated with rituximab developed SARS-CoV-2 infections requiring hospitalization, and one (14.2%) died due to respiratory failure [8]. We also found 10 COVID-19 patients with RMD who were treated with rituximab in the current literature. These 10 patients were from various case reports and case series. Of these 10 patients, 8 had bilateral pneumonia requiring hospitalization and supplementary oxygen and three died [9, 15–20]. All these reports suggest a possible association between rituximab treatment for RMDs and poor prognoses for SARS-CoV-2 infected patients, but no study to date has analyzed the risk of SARS-CoV-2 infection and prognosis of such patients.

Rituximab is a chimeric monoclonal anti-CD20 antibody that has been approved for treating RA that is unresponsive to initial biological DMARD treatment, microscopic polyangiitis, and granulomatosis with polyangiitis. It is also widely used for treating other systemic diseases, such as SLE, Sjögren syndrome, systemic sclerosis, and idiopathic inflammatory myopathies. Several studies have described the effect of rituximab on the B cell cytokine network, mainly on B effector and B regulator cells, with a secondary influence on T helper cell response [21, 22]. Some studies have reported a higher risk of infection in RA patients treated with rituximab than those treated with other biologic DMARDs [23, 24] but these data come from registries and retrospective studies, which may contain bias due to their observational designs. The effects of rituximab on the immune system response to SARS-CoV-2 infection have yet to be elucidated.

Notably, one of our study’s strengths is the fact that it is the first study in which all rituximab-treated patients for their RMD from the same hospital were clinically screened for SARS-COV-2 infection and had their disease characteristics and outcomes thoroughly reported on. This is relevant given that the possible association between rituximab treatment and poor prognoses was made based on case reports or case series, and information about the total cohort of patients treated with rituximab from which they come from is lacking.

However, our study’s main limitation is that our cohort was assessed retrospectively and it does not have a control group. Our cohort exhibited comorbidities such as hypertension COPD/asthma and ILD which are associated with poor prognoses [6] and may have influenced the results. Besides, our cohort size was relatively small and comparisons between groups could not be performed.

In conclusion, ours is the first systematic report on SARS-CoV-2 infection among RMD patients who were treated with rituximab. This cohort exhibited a high rate of severe infection requiring hospitalization (61.5%), with bilateral pneumonia and hyperinflammation leading to a high mortality rate (23.1%). Therefore, treatment with rituximab should be considered a possible risk factor for unfavorable outcomes in COVID-19 patients with RMD. However, further study is necessary to confirm this association.

Author contributions

All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by all authors. The first draft of the manuscript was written by JLM and AGF, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Funding

No specific funding was received from any bodies in the public, commercial or not-for-profit sectors to carry out the work described in this article.

Compliance with ethical standards

Conflict of interest

Dr. Loarce-Martos reports personal fees from Celgene S.L.U., outside the submitted work; Dr. García-Fernández has nothing to disclose; Dr. López-Gutiérrez has nothing to disclose; Dr. García-García has nothing to disclose; Dr. Calvo-Sanz has nothing to disclose; Dr. del Bosque-Granero has nothing to disclose; Dr. Terán-Tinedo has nothing to disclose; Dr. Boteanu has nothing to disclose; Dr. Bachiller-Corral has nothing to disclose; Dr. Vázquez-Díaz reports personal fees and non-financial support from Sandoz, personal fees and non-financial support from Pfizer, personal fees and non-financial support from Merck Sharp and Dohme, outside the submitted work.

Ethical approval

The current study is a sub-analysis of a larger study focused in SARS-CoV-2 infection in RMD patients (study number: 136/20), and was approved by the local ethics committee of our hospital (comité de ética de la investigación con medicamentos del Hospital Universitario Ramón y Cajal) on 05/05/2020. All patients provided informed consent to participate and for publication prior to their inclusion.